PDCD1 and non-small cell lung carcinoma: To target LAG-3, researchers are exploring the use of a soluble dimeric recombinant LAG-3 (eftilagimod alpha, or IMP321), which stimulates DCs through the binding with the major histocompatibility complex (MHC) class II receptor, leading to sustained immune responses when combined with anti-PD-1 therapy in patients with previously untreated unresectable or metastatic NSCLC [NCT03625323 (177)].